ArchiMed will establish a US presence with the launch of a new office, Private Equity International has learned.
The Lyon-based healthcare investor will set up an office to support international expansion for its portfolio companies in the next few months, managing partner Denis Ribon told PEI. The firm has not yet selected a destination, but is considering the north-eastern seaboard.
ArchiMed’s investment mandate allows for US acquisitions but the firm does not intend to pursue them at this time, Ribon said. It has previously completed US mergers and acquisitions for its portfolio companies and will continue to do so from the new office.
Two new partners – both from industry – have joined ArchiMed ahead of its move, Ribon noted. Benoît Adelus joins from diagnostics manufacturer Sebia, where he served as chairman and chief executive, while André-Michel Ballester most recently served as a senior advisor at London-based medical manufacturer LivaNova.
The firm is investing its second fund, a €315 million 2017-vintage. It targets “growth buyout” opportunities in biotech, life sciences and healthcare companies across Western Europe, Ribon added.
Ribon served as global head of healthcare & co-head of France at 3i Group before founding ArchiMed in 2014.